Pfizer
235 East 42nd Street
New York, NY 10017
United States
Tel: (212) 733-2323
Website: https://www.pfizer.com/
About Pfizer
Join world-class scientists and leaders who are dedicated to bringing therapies that will significantly improve patients' lives.
As one of the world's premier innovative biopharmaceutical companies, we're driven to discover the cure --driven to significantly improve the lives of everyone...everywhere. If you're similarly driven, you'll find there's no better place to begin --and continue --your career than at Pfizer.
Science is the foundation of our company. This is why it's no surprise that the most driven scientists in the world choose to carry out their life's passion at Pfizer. We arm them with the resources, technology, and facilities they need to solve some of the world’s most complex health challenges. This combination empowers our scientists with expertise in vaccines, small-molecule medicines, biotherapeutics amongst many others, to collaborate on breakthrough science, including the world's first mRNA-Based Covid19 vaccine. Our colleagues advance science and technologies into the therapies that matter most.
Join us and you'll partner with colleagues of diverse backgrounds and abilities who contribute to all aspects of what we do. Great things happen when people come together with one shared goal. If you're driven to discover the cure- ensure it has the latest technology to make it a reality or help improve the lives of others- join those who are similarly driven at Pfizer. The future of medicine is happening here.
Visit www.pfizer.com and connect with us.
We look different ways. We live different ways. But at Pfizer, we share one goal. We are all…driven to discover the cure. Come and discover what we are all about.
5269 articles with Pfizer
-
On Wednesday, the FDA authorized new Omicron-specific booster shots for Pfizer-BioNTech and Moderna’s COVID-19 vaccines despite a lack of human data.
-
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.1-Adapted Bivalent COVID-19 Vaccine Booster in European Union
9/1/2022
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced a 30-µg booster dose of their Omicron BA.1 Bivalent COVID-19 Vaccine (COMIRNATY® Original/Omicron BA.1 15/15 µg) has been recommended for conditional marketing authorization (cMA) by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) for individuals 12 years and older.
-
Pfizer Invites Public to View and Listen to Two Webcasts of Pfizer Discussions at Healthcare Conferences
9/1/2022
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to two upcoming webcasts of Pfizer discussions at healthcare conferences.
-
Pfizer and BioNTech Granted FDA Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster for Ages 12 Years and Older
8/31/2022
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) of a 30-µg booster dose of the Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original [15 µg] and Omicron BA.4/BA.5 [15 µg]) for individuals ages 12 years and older.
-
Pfizer signaled its interest in longevity research through a new partnership -and a $500,000 investment - in a decentralized drug development program driven by VitaDAO.
-
NCCN Announces Collaboration with Myovant Sciences and Pfizer to Support Projects to Understand and Mitigate Cardiovascular Risk in Patients with Prostate Cancer
8/30/2022
The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) today announced a collaboration with Pfizer and Myovant Sciences to fund research projects seeking to improve cardiovascular management of patients with prostate cancer being treated with androgen-deprivation therapy (ADT).
-
Analysis Group and Pfizer Present Interim Data on COVID-19 Vaccine Safety Surveillance Program Showing No Adverse Safety Signals Among US Veterans Health Administration Patients
8/30/2022
During the International Society of Pharmacoepidemiology's annual meeting, researchers from Analysis Group (a global leader in health care consulting), the Veterans Health Administration (VHA), and Pfizer presented interim data from 1,448,043 US veterans who were among the first to receive the Pfizer-BioNTech COVID-19 vaccine, between December 11, 2020, and September 24, 2021.
-
89bio presented positive data for pegozafermin in SHTG, Tonix enrolled its first patient with Long COVID for TNX-102, Belite enrolled patients with STGD1 and more clinical trial news.
-
The FDA is keeping busy as summer winds down, with approvals, Orphan Drug Designations and other actions. Here’s what the agency has been up to this week.
-
Finding a job right out of college can seem like a daunting task. To help, BioSpace has compiled a list of the top companies hiring new grads for entry-level roles.
-
Moderna announced it is filing lawsuits against Pfizer and BioNTech, alleging that the companies’ COVID-19 vaccine infringes patents covering its mRNA technology.
-
Pfizer and BioNTech Complete Submission to European Medicines Agency for Omicron BA.4/BA.5 Adapted Bivalent Vaccine
8/26/2022
Pfizer Inc. and BioNTech SE announced they have completed a submission to the European Medicines Agency for a booster dose of an Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine for individuals 12 years of age and older.
-
Moderna Sues Pfizer and BioNTech for Infringing Patents Central to Moderna's Innovative mRNA Technology Platform
8/26/2022
Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today is filing patent infringement lawsuits against Pfizer and BioNTech in the United States District Court for the District of Massachusetts and the Regional Court of Düsseldorf in Germany.
-
Pfizer's RSV vaccine has produced promising data with an efficacy of 85.7% in adults over 60 with a more severe form of the disease. Data in hand, Pfizer plans to head to the FDA this Fall.
-
Pfizer Announces Positive Top-Line Data from Phase 3 Trial of Older Adults for its Bivalent Respiratory Syncytial Virus (RSV) Vaccine Candidate
8/25/2022
Pfizer Inc. announced positive top-line data from the Phase 3 clinical trial RENOIR investigating its bivalent RSV prefusion F vaccine candidate, RSVpreF, when administered to adults 60 years of age or older.
-
According to a recent study, Pfizer’s Paxlovid appeared to be far more effective at reducing deaths and hospitalizations in older adults than younger patients suffering from the Omicron variant of COVID-19.
-
A day after Pfizer and partner BioNTech submitted an EUA request to the FDA for their booster shot targeting Omicron variants BA.4 and BA.5, the regulator appears close to approving it.
-
Pfizer and BioNTech Announce Updated COVID-19 Vaccine Data Supporting Efficacy in Children 6 Months through 4 Years of Age
8/23/2022
Pfizer Inc. and BioNTech SE announced updated efficacy results from a Phase 2/3 trial evaluating a three 3-µg dose series of the Pfizer-BioNTech COVID-19 Vaccine in children 6 months through 4 years of age, reinforcing previously reported interim vaccine efficacy data collected in March and April 2022.
-
Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine
8/22/2022
Pfizer Inc. and BioNTech SE announced they have completed a submission to the U.S. Food and Drug Administration requesting Emergency Use Authorization of a booster dose of an Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine for individuals 12 years of age and older.
-
Pfizer is to report initial data from a randomized trial of the second course of therapy of paxlovid in COVID-19 rebound patients by Sept. 2023.